Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Iovance (IOVA) Extends Timeline for Rolling BLA of Melanoma Drug
01:32pm, Monday, 21'st Nov 2022
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
Why Iovance Biotherapeutics Is Crashing Today
01:06pm, Friday, 18'th Nov 2022
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.
Iovance's stock is down after receiving FDA feedback on application for new melanoma drug
09:00am, Friday, 18'th Nov 2022
Shares of Iovance Biotherapeutics Inc. IOVA, -2.61% fell 11.4% in premarket trading on Friday after the company said it received feedback from the Food and Drug Administration on its submission for li
Iovance Biotherapeutics, Inc. (IOVA) Q3 2022 Earnings Call Transcript
08:57pm, Thursday, 03'rd Nov 2022
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President of Investor Relations and Corporat
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
04:01pm, Monday, 24'th Oct 2022
SAN CARLOS, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report
Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study
01:32pm, Tuesday, 11'th Oct 2022
Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.
Iovance (IOVA) Focuses on Seeking Nod for Melanoma Therapy
11:17am, Wednesday, 05'th Oct 2022
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
Oral Presentation of C-144-01 Trial Cohorts 2 and 4 Oral Presentation of C-144-01 Trial Cohorts 2 and 4
Iovance Biotherapeutics Approaches Key Regulatory Milestone As Clinical Momentum Accelerates
09:00am, Tuesday, 27'th Sep 2022
Shares have fallen by nearly 50% so far in 2022. Admittedly, Iovance has suffered multiple setbacks including CEO exit, delays in timelines and obstacles on path to gaining regulatory approval.
Iovance Biotherapeutics to Present at Upcoming Conferences
04:01pm, Tuesday, 06'th Sep 2022
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
5 Top Stocks Cathie Wood Is Selling This Week
04:53pm, Friday, 26'th Aug 2022
Shares of Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ) closed the week down about 2.5%, losing out on earlier gains during the week. However, retail inve
Iovance (IOVA) Starts Rolling BLA With FDA for Melanoma Therapy
02:18pm, Friday, 26'th Aug 2022
Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 202
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
01:33pm, Friday, 05'th Aug 2022
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance Biotherapeutics, Inc. (IOVA) CEO Fred Vogt on Q2 2022 Results - Earnings Call Transcript
11:18pm, Thursday, 04'th Aug 2022
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor & Public Relations & Corp
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
07:00am, Wednesday, 27'th Jul 2022
SAN CARLOS, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report
